A changing treatment landscape for multiple sclerosis: challenges and opportunities
Author:
- 17 March 2014
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 275 (4) , 364-381
Abstract
Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion ofMSpatients will develop neurological disability over time and up until recently treatment options have been limited. However,MStreatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long‐term safety issues and efficacy, not least in patients with progressive disease.Keywords
This publication has 87 references indexed in Scilit:
- Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid BiomarkersPLOS ONE, 2013
- Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugsMultiple Sclerosis Journal, 2012
- Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelinationActa Neuropathologica, 2012
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- Evidence for a two-stage disability progression in multiple sclerosisBrain, 2010
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisThe Lancet Neurology, 2010
- Multiple sclerosisThe Lancet, 2008
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences, 2006